Zacks Investment Research cut shares of ELEKTA (NASDAQ:EKTAY) from a buy rating to a hold rating in a research note issued to investors on Friday.
According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “
Shares of ELEKTA (EKTAY) opened at 9.63 on Friday. ELEKTA has a 1-year low of $7.97 and a 1-year high of $11.18.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/10/31/elekta-ektay-stock-rating-lowered-by-zacks-investment-research.html.
ELEKTA Company Profile
Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about ELEKTA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ELEKTA and related companies.